Literature DB >> 27866223

Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus.

Nasim Samandari1, Aashiq H Mirza1,2, Lotte B Nielsen1, Simranjeet Kaur1, Philip Hougaard3, Siri Fredheim1, Henrik B Mortensen1,4, Flemming Pociot5,6,7.   

Abstract

AIMS/HYPOTHESIS: We aimed to identify circulating microRNA (miRNA) that predicts clinical progression in a cohort of 123 children with new-onset type 1 diabetes mellitus.
METHODS: Plasma samples were prospectively obtained at 1, 3, 6, 12 and 60 months after diagnosis from a subset of 40 children from the Danish Remission Phase Cohort, and profiled for miRNAs. At the same time points, meal-stimulated C-peptide and HbA1c levels were measured and insulin-dose adjusted HbA1c (IDAA1c) calculated. miRNAs that at 3 months after diagnosis predicted residual beta cell function and glycaemic control in this subgroup were further validated in the remaining cohort (n = 83). Statistical analysis of miRNA prediction for disease progression was performed by multiple linear regression analysis adjusted for age and sex.
RESULTS: In the discovery analysis, six miRNAs (hsa-miR-24-3p, hsa-miR-146a-5p, hsa-miR-194-5p, hsa-miR-197-3p, hsa-miR-301a-3p and hsa-miR-375) at 3 months correlated with residual beta cell function 6-12 months after diagnosis. Stimulated C-peptide at 12 months was predicted by hsa-miR-197-3p at 3 months (p = 0.034). A doubling of this miRNA level corresponded to a sixfold higher stimulated C-peptide level. In addition, a doubling of hsa-miR-24-3p and hsa-miR-146a-5p levels at 3 months corresponded to a 4.2% (p < 0.014) and 3.5% (p < 0.022) lower IDAA1c value at 12 months. Analysis of the remaining cohort confirmed the initial finding for hsa-miR-197-3p (p = 0.018). The target genes for the six miRNAs revealed significant enrichment for pathways related to gonadotropin-releasing hormone receptor and angiogenesis pathways. CONCLUSIONS/
INTERPRETATION: The miRNA hsa-miR-197-3p at 3 months was the strongest predictor of residual beta cell function 1 year after diagnosis in children with type 1 diabetes mellitus.

Entities:  

Keywords:  Biomarkers; Children; Residual beta cell function; miRNA

Mesh:

Substances:

Year:  2016        PMID: 27866223     DOI: 10.1007/s00125-016-4156-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  beta-Cell death during progression to diabetes.

Authors:  D Mathis; L Vence; C Benoist
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

3.  MicroRNAs in metabolism and metabolic diseases.

Authors:  V Rottiers; S H Najafi-Shoushtari; F Kristo; S Gurumurthy; L Zhong; Y Li; D E Cohen; R E Gerszten; N Bardeesy; R Mostoslavsky; A M Näär
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-12-12

4.  Circulating miRNA profiles in patients with metabolic syndrome.

Authors:  Dwi Setyowati Karolina; Subramaniam Tavintharan; Arunmozhiarasi Armugam; Sugunavathi Sepramaniam; Sharon Li Ting Pek; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  J Clin Endocrinol Metab       Date:  2012-10-02       Impact factor: 5.958

5.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

6.  miR-375 maintains normal pancreatic alpha- and beta-cell mass.

Authors:  Matthew N Poy; Jean Hausser; Mirko Trajkovski; Matthias Braun; Stephan Collins; Patrik Rorsman; Mihaela Zavolan; Markus Stoffel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

7.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

Authors:  Hadi Valadi; Karin Ekström; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan O Lötvall
Journal:  Nat Cell Biol       Date:  2007-05-07       Impact factor: 28.824

8.  Molecular signatures differentiate immune states in type 1 diabetic families.

Authors:  Yi-Guang Chen; Susanne M Cabrera; Shuang Jia; Mary L Kaldunski; Joanna Kramer; Sami Cheong; Rhonda Geoffrey; Mark F Roethle; Jeffrey E Woodliff; Carla J Greenbaum; Xujing Wang; Martin J Hessner
Journal:  Diabetes       Date:  2014-04-23       Impact factor: 9.461

9.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.

Authors:  Jun-Hao Li; Shun Liu; Hui Zhou; Liang-Hu Qu; Jian-Hua Yang
Journal:  Nucleic Acids Res       Date:  2013-12-01       Impact factor: 16.971

10.  Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients.

Authors:  Cristhianna V A Collares; Adriane F Evangelista; Danilo J Xavier; Diane M Rassi; Thais Arns; Maria C Foss-Freitas; Milton C Foss; Denis Puthier; Elza T Sakamoto-Hojo; Geraldo A Passos; Eduardo A Donadi
Journal:  BMC Res Notes       Date:  2013-11-26
View more
  24 in total

Review 1.  Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?

Authors:  G Sebastiani; L Nigi; G E Grieco; F Mancarella; G Ventriglia; F Dotta
Journal:  J Endocrinol Invest       Date:  2017-02-17       Impact factor: 4.256

Review 2.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

3.  Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.

Authors:  Rose A Gubitosi-Klug; Barbara H Braffett; Susan Hitt; Valerie Arends; Diane Uschner; Kimberly Jones; Lisa Diminick; Amy B Karger; Andrew D Paterson; Delnaz Roshandel; Santica Marcovina; John M Lachin; Michael Steffes; Jerry P Palmer
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

4.  Overexpression of miR-130a-3p/301a-3p attenuates high glucose-induced MPC5 podocyte dysfunction through suppression of TNF-α signaling.

Authors:  Yan Jiang; Wei Wang; Zong-Yang Liu; Yi Xie; Yuan Qian; Xue-Ni Cai
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

5.  Serum miR-204 is an early biomarker of type 1 diabetes-associated pancreatic beta-cell loss.

Authors:  Guanlan Xu; Lance A Thielen; Junqin Chen; Truman B Grayson; Tiffany Grimes; S Louis Bridges; Hubert M Tse; Blair Smith; Rakesh Patel; Peng Li; Carmella Evans-Molina; Fernando Ovalle; Anath Shalev
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-08-13       Impact factor: 4.310

6.  Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions.

Authors:  Benjamin Udoka Nwosu
Journal:  Eur Med J Diabetes       Date:  2019-03-14

7.  miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes.

Authors:  Giuliana Ventriglia; Francesca Mancarella; Guido Sebastiani; Dana P Cook; Roberto Mallone; Chantal Mathieu; Conny Gysemans; Francesco Dotta
Journal:  Diabetologia       Date:  2019-10-28       Impact factor: 10.122

8.  Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion.

Authors:  Isaac Snowhite; Ricardo Pastori; Jay Sosenko; Shari Messinger Cayetano; Alberto Pugliese
Journal:  Diabetes       Date:  2020-12-04       Impact factor: 9.461

Review 9.  Type 1 Diabetes Candidate Genes Linked to Pancreatic Islet Cell Inflammation and Beta-Cell Apoptosis.

Authors:  Joachim Størling; Flemming Pociot
Journal:  Genes (Basel)       Date:  2017-02-16       Impact factor: 4.096

10.  Serum miRNA levels are related to glucose homeostasis and islet autoantibodies in children with high risk for type 1 diabetes.

Authors:  Linda Åkerman; Rosaura Casas; Johnny Ludvigsson; Beatriz Tavira; Camilla Skoglund
Journal:  PLoS One       Date:  2018-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.